PDCD1 and melanoma: This is in line with the previously mentioned transcriptomic signatures of residual MAPKi-treated melanoma that resembles an innate anti-PD-1 resistance (IPRES) signature 109, 110 and the clinical observations that anti-PD-1 therapy is less effective immediately following BRAF inhibition 116.